May, 2024
May 2024
Joe Daccache: The realm of ADCs and their potential in oncology
Apr 14, 2024, 02:34

Joe Daccache: The realm of ADCs and their potential in oncology

Joe Daccache, Engagement Manager at DeciBio, shared a post on LinkedIn:

“As we witness remarkable progress in the realm of ADCs and their potential in oncology, the horizon is expanding, unveiling a wealth of opportunities in non-oncological applications.

Exploring New Frontiers: While oncology has been the primary focus of ADC research, there’s a notable surge in interest and activity exploring non-oncology applications. From metabolic diseases such as diabetes (e.g., Amgen) to autoimmune conditions such as arthritis (e.g., Regeneron, AbbVie) and even viral infections like influenza (e.g., Cidara Therapeutics), the potential for ADCs to revolutionize treatment across diverse therapeutic areas is immense.

Diverse Applications, Wide Targets: These conjugates utilize noncytotoxic payloads such as steroids (e.g., Abbive) , ASOs (e.g., Avidity Biosciences, Dyne Therapeutics, miRecule), antibacterial (e.g., Otsuka Pharmaceutical Companies), etc., and bind to a wide variety of targets including bacterial membranes, vascular proteins, and more. This versatility opens up a world of possibilities in a multitude of diseases.

Rapid Progress: The strides made so far are just the beginning. Data showcasing the therapeutic efficacy of ADCs in non-oncology settings are not just promising but downright striking. The exponential growth in interest and work in these areas underscores the burgeoning potential waiting to be unlocked.

Untapped Opportunities, Growth in Deals: Despite the remarkable progress, it’s evident that non-oncology applications of ADCs still remain relatively underexplored. However, recent deals and collaborations, such as the Bristol Myers Squibb and Avidity Biosciences, Inc. partnerships in cardiology, underscore the growing recognition of ADCs’ potential beyond oncology. These ventures serve as strong indicators of the promise and excitement this modality holds.

Addressing Challenges: While the journey towards leveraging ADCs in non-oncological diseases is rife with opportunities, it’s not without its challenges. From regulatory considerations to the need for site-specific delivery to minimize side effects, there’s much ground to cover. Yet, these challenges present avenues for innovation and collaboration, propelling us towards a future where ADCs play a pivotal role in treating a myriad of conditions

Early pioneering work in employing E-selectin-directed immunoconjugates to deliver dexamethasone to activated endothelial cells paved the way for exploration in various non-oncological conditions. While ADCs have rightfully earned their place in oncology, their journey into non-oncological realms remains early but is a testament to their versatility and potential to revolutionize treatment paradigms across therapeutic domains.

What are your thoughts on the evolving landscape of ADCs? I’d love to hear your insights and perspectives in the comments below!”

Source: Joe Daccache/LinkedIn